Jazz Pharmaceuticals (JAZZ) Gross Margin (2010 - 2026)

Jazz Pharmaceuticals' Gross Margin history runs 17 years deep, the most recent figure standing at 87.45% for Q1 2026.

• In Q1 2026, Gross Margin fell 89.0% year-over-year to 87.45%; the TTM figure through Mar 2026 stood at 88.0% (down 81.0% YoY), while the FY2025 annual figure was 88.21%, down 84.0% from the prior year.
• Gross Margin was 87.45% for Q1 2026 at Jazz Pharmaceuticals, roughly flat from 87.18% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 89.81% in Q2 2023 to a low of 82.78% in Q4 2022.
• Historically, Gross Margin has averaged 87.77% across 5 years, with a median of 88.35% in 2025.
• The sharpest annual moves came in 2022 and 2023: Gross Margin slumped 755 bps in 2022, then surged 662 bps in 2023.
• A 5-year view of Gross Margin shows it stood at 82.78% in 2022, then gained by 8 bps to 89.4% in 2023, then slipped by 1 bps to 88.17% in 2024, then dropped by 1 bps to 87.18% in 2025, then gained by 0 bps to 87.45% in 2026.
• The last three Gross Margin figures came in at 87.45% (Q1 2026), 87.18% (Q4 2025), and 88.56% (Q3 2025), per Business Quant data.